NCT04747496

Brief Summary

The safety of edoxaban treatment will be examined using real-world clinical evidence from adult patients with non-valvular atrial fibrillation (NVAF) indications in routine clinical practice.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2021

Typical duration for all trials

Geographic Reach
1 country

97 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 5, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 10, 2021

Completed
16 days until next milestone

Study Start

First participant enrolled

February 26, 2021

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 27, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 27, 2024

Completed
Last Updated

January 9, 2025

Status Verified

January 1, 2025

Enrollment Period

3.8 years

First QC Date

February 5, 2021

Last Update Submit

January 7, 2025

Conditions

Keywords

Non-valvular atrial fibrillationEdoxaban

Outcome Measures

Primary Outcomes (4)

  • Incidence (including 95% confidence intervals) of major bleeding events following edoxaban treatment

    Baseline up to 2 years post treatment

  • Incidence (including 95% confidence intervals) of clinically related non-major bleeding events following edoxaban treatment

    Baseline up to 2 years post treatment

  • Incidence (including 95% confidence intervals) of adverse events/adverse drug reactions following edoxaban treatment

    Baseline up to 2 years post treatment

  • Incidence (including 95% confidence intervals) of mortality (cardiovascular and all-cause) following edoxaban treatment

    Baseline up to 2 years post treatment

Secondary Outcomes (11)

  • Incidence (including 95% confidence intervals) of stroke (ischemic and hemorrhagic) following edoxaban treatment

    Baseline up to 2 years post treatment

  • Incidence (including 95% confidence intervals) of systemic embolic event (SEE) following edoxaban treatment

    Baseline up to 2 years post treatment

  • Incidence (including 95% confidence intervals) of transient ischemic attack (TIA) following edoxaban treatment

    Baseline up to 2 years post treatment

  • Incidence (including 95% confidence intervals) of major adverse cardiovascular events (MACE) following edoxaban treatment

    Baseline up to 2 years post treatment

  • Incidence (including 95% confidence intervals) of venous thromboembolism (VTE) following edoxaban treatment

    Baseline up to 2 years post treatment

  • +6 more secondary outcomes

Study Arms (1)

NVAF patients

NVAF adult patients with one or more risk factors treated with edoxaban.

Drug: Edoxaban

Interventions

This is a non-interventional, observational study.

NVAF patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with NVAF treated with edoxaban will be enrolled in this non-interventional, observational study.

You may qualify if:

  • Written, informed consent
  • NVAF-patients treated with edoxaban according to packaging information (i.e., for NVAF adult patients with one or more risk factors (such as history of congestive heart failure, hypertension, age ≥75 years old, diabetes, prior stroke or TIA) in prevention of stroke and systemic circulation embolism)
  • Not participating in any interventional study at the same time

You may not qualify if:

  • Not applicable

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (97)

Beijing Tsinghua Changgung Hospital Affiliated Hospital of Tsinghua University

Beijing, Changping District, China

Location

Aviation General Hospital of China Medical University

Beijing, Chaoyang District, China

Location

Beijing Anzhen Hospital, Capital Medical University

Beijing, Chaoyang District, China

Location

Beijing Chao-Yang Hospital Capital Medical University

Beijing, Chaoyang District, China

Location

Beijing Hospital

Beijing, Dongcheng District, China

Location

Beijing Tongren Hospital,Cmu

Beijing, Dongcheng District, China

Location

The First Hospital of Lanzhou University

Lanzhou, Gansu, China

Location

Guangdong Second Provincial General Hospital

Guangzhou, Guangdong, China

Location

Guangzhou First People'S Hospital

Guangzhou, Guangdong, China

Location

Guangzhou Panyu Central Hospital

Guangzhou, Guangdong, China

Location

Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University

Guangzhou, Guangdong, China

Location

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Location

The First Affiliated Hospital of Jinan University

Guangzhou, Guangdong, China

Location

The First Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China

Location

The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Location

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Location

The First People'S Hospital of Nanning

Nanjing, Guangxi, China

Location

The Third People'S Hospital of Nanning

Nanning, Guangxi, China

Location

Heilongjiang Provincial Hospital

Harbin, Heilongjiang, China

Location

Kaifeng Central Hospital

Kaifeng, Henan, China

Location

The Third Affiliated Hospital of Xinxiang Medical University

Xinxiang, Henan, China

Location

Xinxiang Central Hospital

Xinxiang, Henan, China

Location

The Fifth Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Location

The Second Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Location

Tianjin Medical University General Hospital

Tianjin, Heping District, China

Location

The Second Hospital of Tianjin Medical University

Tianjin, Hexi District, China

Location

Shanghai Ninth People'S Hospital,Shanghai Jiaotong University School of Medicine

Shanghai, Huangpu District, China

Location

Hebei Petro China Center Hospital

Langfang, Hubei, China

Location

Dongfeng General Hospital of Chinese Medicine

Shiyan, Hubei, China

Location

Renmin Hospital of Wuhan University Hubei General Hospital

Wuhan, Hubei, China

Location

The Central Hospital of Wuhan

Wuhan, Hubei, China

Location

Tongji Hospital,Tongji Medical College Huazhong University of Science & Technology

Wuhan, Hubei, China

Location

Union Hospital Affiliated With Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, China

Location

Wuhan Puai Hospital

Wuhan, Hubei, China

Location

Wuhan Third Hospital

Wuhan, Hubei, China

Location

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China

Location

Changsha Central Hospital

Changsha, Hunan, China

Location

Hunan Provincial People'S Hospital

Changsha, Hunan, China

Location

The First Hospital of Changsha

Changsha, Hunan, China

Location

The Fourth Hospital of Changsha

Changsha, Hunan, China

Location

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China

Location

Xiangtan Central Hospital

Xiangtan, Hunan, China

Location

Changzhou No.2 People'S Hospital

Changzhou, Jiangsu, China

Location

Jiangyin People'S Hospital

Jiangyin, Jiangsu, China

Location

The First People'S Hospital of Kunshan

Kunshan, Jiangsu, China

Location

Jiangxi Provincial People'S Hospital

Nanchang, Jiangsu, China

Location

Nanjing Jiangning Hospital

Nanjing, Jiangsu, China

Location

The Second Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

Location

The Second People'S Hospital of Suzhou

Suzhou, Jiangsu, China

Location

Affiliated Hospital of Jiangnan University

Wuxi, Jiangsu, China

Location

Wuxi People'S Hospital

Wuxi, Jiangsu, China

Location

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

Location

Xuzhou Central Hospital

Xuzhou, Jiangsu, China

Location

Jilin Province People'S Hospital

Changchun, Jilin, China

Location

The Fourth Hospital of Jilin University

Changchun, Jilin, China

Location

The Second Hospital of Jilin University

Changchun, Jilin, China

Location

The First Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, China

Location

China Shenyang Chest Hospital

Shenyang, Liaoning, China

Location

The Second Affiliated Hospital of Shenyang Medical College

Shenyang, Liaoning, China

Location

Beijing Miyun District Hospital

Beijing, Minyun District, China

Location

Shanghai East Hospital,Tongji University

Shanghai, Pudong New Area, China

Location

Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University

Shanghai, Qingpu District, China

Location

The Fifth People'S Hospital of Jinan

Jinan, Shandong, China

Location

Affiliated Hospital of Weifang Medical University

Weifang, Shandong, China

Location

Hangzhou Third Hospital

Hangzhou, Shangcheng District, China

Location

Heping Hospital Affiliated to Changzhi Medical College

Changzhi, Shanxi, China

Location

Shanxi Bethune Hospital

Taiyuan, Shanxi, China

Location

Shanxi Cardiovascular Hospital

Taiyuan, Shanxi, China

Location

Shanxi Provincial People'S Hospital

Taiyuan, Shanxi, China

Location

Taiyuan Central Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

Location

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Location

Beijing Chest Hospital, Capital Medical University

Beijing, Tongzhou District, China

Location

Peking Union Medical College Hospital

Beijing, Xicheng District, China

Location

Peking University First Hospital

Beijing, Xicheng District, China

Location

The First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China

Location

Xuanwu Hospital Capital Medical University

Beijing, Xuanwu District, China

Location

Longhua Hospital Shanghai University of Traditional Chinese Medicine

Shanghai, Xuhui District, China

Location

Shanghai Yangpu East Hospital

Shanghai, Yangpu District, China

Location

The First Hospital of Kunming

Kunming, Yunnan, China

Location

Chongqing General Hospital

Chongqing, Yuzhong District, China

Location

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Yuzhong District, China

Location

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Yuzhong District, China

Location

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Location

Zhejiang Greentown Cardiovascular Hospital

Hangzhou, Zhejiang, China

Location

Zhejiang Hospital

Hangzhou, Zhejiang, China

Location

Zhejiang Provincial Hospital of Chinese Medicine

Hangzhou, Zhejiang, China

Location

Zhejiang Provincial People'S Hospital

Hangzhou, Zhejiang, China

Location

The First Hospital of Jiaxing

Jiaxing, Zhejiang, China

Location

The Second Hospital of Jiaxing

Jiaxing, Zhejiang, China

Location

Ningbo First Hospital

Ningbo, Zhejiang, China

Location

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Location

Wenzhou Central Hospital

Wenzhou, Zhejiang, China

Location

Wenzhou Hospital of Traditional Chinese Medicine

Wenzhou, Zhejiang, China

Location

Wenzhou People'S Hospital

Wenzhou, Zhejiang, China

Location

Beijing Chao-Yang Hospital Capital Medical University

Beijing, China

Location

Tsinghua University Affiliated Beijing Tsinghua Changgeng Hospital

Beijing, China

Location

The Fourth Hospital of Changhsa

Changsha, China

Location

MeSH Terms

Interventions

edoxaban

Study Officials

  • Global Clinical Leader

    Daiichi Sankyo

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 5, 2021

First Posted

February 10, 2021

Study Start

February 26, 2021

Primary Completion

November 27, 2024

Study Completion

November 27, 2024

Last Updated

January 9, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will share

De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Shared Documents
STUDY PROTOCOL, SAP, CSR
Time Frame
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access Criteria
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
More information

Locations